UK-based specialist pharmaceutical firm Midatech Pharma has submitted a clinical trial application (CTA) for its drug candidate MTD201 to treat carcinoid cancer and acromegaly.

Utilising the firm’s sustained release platform, MTD201 is designed to deliver a long-acting dose of a somatostatin analogue called octreotide that is being developed as an alternative treatment to existing Sandostatin LAR (SLAR).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

MTD201 is manufactured using Midatech’s Q-Sphera microsphere platform with micro-fluidic technology to obtain a precision sustained release particle formulation.

The new trial is planned to establish that MTD201 can be interchanged pharmacokinetically and / or pharmacodynamically and by extrapolation with SLAR.

Additionally, the trial aims to validate that MTD201 will achieve equivalent therapeutic control of growth hormone, while providing an alternative to SLAR in active acromegaly patients.

“MTD201 will provide a much-needed addition to currently available therapies for the treatment of carcinoid cancer and acromegaly.”

Midatech Pharma CEO Dr Jim Phillips said: “MTD201 will provide a much-needed addition to currently available therapies for the treatment of carcinoid cancer and acromegaly.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“This clinical trial is the culmination of more than five years of development and is a key value inflection point for our proprietary sustained release technology platform as it moves into the clinic for the first time on track for Q4 2017.”

The MTD201 clinical programme is expected to be initiated in the fourth quarter of this year and is scheduled to be completed in the first half of next year.

It is anticipated that in comparison to SLAR, MTD201 will feature fast and simple reconstitution with less errors and wastage, decreased pain on injection due to use of small syringe needle and volume, and improved economics.